Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1320-1326

  Bishop, M R ^a   Iversen, P L ^a   Bayever, E ^a   Sharp, J G ^a   Greiner, T C ^a   Copple, B L ^a   Ruddon, R ^a   Zon, G ^a   Spinolo, J ^a   Arneson, M ^a   Armitage, J O ^a   Kessinger, A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTARABINE; DAUNORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN P53; TIOGUANINE; VANCOMYCIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER TOXICITY; LUNG TOXICITY; MALE; METABOLIC DISORDER; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRELEUKEMIA; PRIORITY JOURNAL; SKIN TOXICITY; TRANSCRIPTION REGULATION;

EID: 9244223546     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1320     Document Type: Article

References (26)

1. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993
2. Bishop JM: Molecular themes in oncogenesis. Cell 64:235-248, 1991
3. Kastan MB: p53: Evolutionary conserved and constantly evolving. J Natl Inst Health Res 5:53-57, 1993
4. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391-2411, 1994
5. Miller C, Mohandas T, Wolf D, et al: Human p53 localized to short arm of chromosome 17. Nature 319:783-784, 1986
6. Fields S, Jang SK: Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1048, 1990
7. Raycroft L, Wu H, Lozano G: Transcriptional activation by wild type but not transforming mutants of the p53 oncogene. Science 249:1049-1051, 1990
8. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
9. Lane DL: p53: Guardian of the genome. Nature 358:15-16, 1992
10. Ginsberg D, Mechta F, Yaniv M, et al: Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88:9979-9983, 1991
11. Kastan MG, Zhan Q, El-Diery WS, et al: A mammalian cell checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71:587-597, 1992
12. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412-2421, 1994
13. Smith LJ, McCulloch EA, Benchimol S: Expression of the p53 oncogene in acute myeloblastic leukemia. J Exp Med 164:751-761, 1986
14. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutics: Is the bullet really magical? Science 261:1004-1012, 1993
15. Ma DDF, Le Doan T: Antisense oligonucleotide therapies: Are they the "magic bullets"? Ann Intern Med 120:161-163, 1994 (editorial)
16. Bayever E, Haines KM, Iversen PL, et al: Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma 12:223-231, 1994
17. Bishop MR, Warkentin PI, Jackson JD, et al: Antisense oligonucleotide OL(1)p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia, in Gee AP, Gross S, Wothington-White DA (eds): Advances in Bone Marrow Purging and Processing: Fourth International Symposium. New York, NY, Wiley-Liss, 1994, pp 183-187
18. Spinolo J, Bayever E, Iversen P, et al: Toxicity of human p53 antisense oligonucleotide infusions in Rhesus macacca. Proc Am Assoc Cancer Res 33:523, 1992 (abstr)
19. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
20. Bergot BJ, Egan W: Separation of synthetic phosphorothioate oligodeoxyribonucleotides from their oxygenated (phosphodiester) defect species by strong ion exchange high performance chromatography. J Chromatogr 559:35-42, 1992
21. 35S-labelled phosphorothioate oligodeoxyribonucleotides by use of hydrogen-phosphate chemistry. Anal Biochem 188:11-16, 1990
22. + spontaneously differentiating cell components. Blood 80:1026-1032, 1992
23. Beck JS, Kwitek AE, Cogen PH, et al: A denaturing gradient gel electropheresis assay for sensitive detection of p53 mutations. Hum Genet 91:25-30, 1993
24. Greiner TC, Moynihan MJ, Chan WC, et al: p53 Mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:1996 (in press)
25. Copple B, Bayever E, Iversen PL, et al: Oligonucleotides directed to p53 mRNA cause increased sensitivity to radical oxygen induced cytotoxicity. Proc Am Assoc Cancer Res 35:307, 1994 (abstr)
26. Bayever E, Haines KM, Copple BL, et al: Interactions between antisense oligonucleotides to p53 mRNA and reactive oxygen in acute myelogenous leukemia. Proc Am Assoc Cancer Res 36:411, 1995 (abstr)